Literature DB >> 29549640

Therapeutic Antibodies for Biodefense.

Arnaud Avril1.   

Abstract

Diseases can be caused naturally by biological agents such as bacteria, viruses and toxins (natural risk). However, such biological agents can be intentionally disseminated in the environment by a State (military context) or terrorists to cause diseases in a population or livestock, to destabilize a nation by creating a climate of terror, destabilizing the economy and undermining institutions. Biological agents can be classified according to the severity of illness they cause, its mortality and how easily the agent can be spread. The Centers for Diseases Control and Prevention (CDC) classify biological agents in three categories (A, B and C); Category A consists of the six pathogens most suitable for use as bioweapons (Bacillus anthracis, Yersinia pestis, Francisella tularensis, botulinum neurotoxins, smallpox and viral hemorrhagic fevers). Antibodies represent a perfect biomedical countermeasure as they present both prophylactic and therapeutic properties, act fast and are highly specific to the target. This review focuses on the main biological agents that could be used as bioweapons, the history of biowarfare and antibodies that have been developed to neutralize these agents.

Entities:  

Keywords:  Antibodies; Biodefense; Bioterrorism; Biowarfare agent; Bioweapon; CBRN; Prophylaxis; Therapeutic; Toxin; Virus

Mesh:

Substances:

Year:  2017        PMID: 29549640     DOI: 10.1007/978-3-319-72077-7_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  1 in total

1.  Ricin Antibodies' Neutralizing Capacity against Different Ricin Isoforms and Cultivars.

Authors:  Maria Lucia Orsini Delgado; Arnaud Avril; Julie Prigent; Julie Dano; Audrey Rouaix; Sylvia Worbs; Brigitte G Dorner; Clémence Rougeaux; François Becher; François Fenaille; Sandrine Livet; Hervé Volland; Jean-Nicolas Tournier; Stéphanie Simon
Journal:  Toxins (Basel)       Date:  2021-01-29       Impact factor: 4.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.